МЕХАНИЧЕСКАЯ ПОДДЕРЖКА КРОВООБРАЩЕНИЯ ПРИ ЧРЕСКОЖНОМ КОРОНАРНОМ ВМЕШАТЕЛЬСТВЕ

Несмотря на стремительное развитие эндоваскулярной хирургии, смертность при чрескожном коронарном вмешательстве (ЧКВ) у пациентов с высокими рисками тяжелых кардиальных осложнений и в критических состояниях (кардиогенный шок, остановка сердечной деятельности) остается крайне высокой. Успех ЧКВ напрямую зависит от способности «кардиокоманды» предотвращать и своевременно купировать тяжелые нарушения сердечной деятельности. На данный момент фармакологическая терапия не способна полноценно бороться с развитием тяжелых кардиальных событий при проведении ЧКВ. Именно поэтому в таких ситуациях использование устройств чрескожной механической поддержки кровообращения (ЧМПК) может оказать неоценимую помощь при лечении данной категории пациентов. Несмотря на то, что в течение нескольких десятилетий устройства ЧМПК используются для стабилизации пациентов при кардиогенном шоке и обеспечения гемодинамической поддержки при ЧКВ высокого риска, результаты их применения остаются неоднозначными. Целью настоящей статьи является обзор современных устройств ЧМПК, имеющихся данных и результатов исследований, показаний для их применения, а также практических моментов их эксплуатации, которые могут помочь в принятии правильного решения по выбору устройств ЧМПК.

механическая поддержка кровообращения, ЧКВ, кардиогенный шок

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J. et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014; 129:e28292. doi: 10.1161/01.cir.0000441139.02102.80

2. Hochman J.S., Sleeper L.A., Webb J.G., Dzavik V., Buller C.E., Aylward P., Col J., White H.D.; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511–2515. DOI: 10.1001/jama.295.21.2511

3. Thiele H., Zeymer U., Neumann F.-J., Ferenc M., Olbrich H.-G., Hausleiter J.et al.; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012; 367:1287–1296. doi: 10.1056/NEJMoa1208410.

4. Rihal C.S., Naidu S.S., Givertz M.M., Szeto W.Y., Burke J.A., Kapur N.K. et al.; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ ACC/HFSA/STS Clinical Expert Consensus Statementon the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology- Association Canadienne de Cardiologie d’intervention. J Am Coll Cardiol. 2015; 65:e7–26. doi: 10.1016/j.jacc.2015.03.036

5. Kantrowitz A., Tjonneland S., Freed P.S., Phillips S.J., Butner A.N., Sherman J.L. Jr. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA. 1968; 203:113–8.

6. Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012; 367: 1287–96. doi: 10.1056/NEJMoa1208410.

7. Perera D., Stables R., Thomas M., Booth J., Pitt M., Blackman D. et al. Elective intra-aortic balloon counterpulsation during high risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010; 304:867–74. doi: 10.1001/jama.2010.1190.

8. Dixon S.R., Henriques J.P., Mauri L., Sjauw K., Civitello A., Kar B. et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. J Am Coll Cardiol Intv. 2009; 2:91–96. doi: 10.1016/j.jcin.2008.11.005.

9. Burkhoff D., O’Neill W., Brunckhorst C., Letts D., Lasorda D., Cohen H.A. Feasibility study of the use of the TandemHeart percutaneous ventricular assist device for treatment of cardiogenic shock. Catheter Cardiovasc Interv. 2006; 68: 211–7. DOI: 10.1002/ccd.20796

10. Napp L.C., Kuhn C., Hoeper M.M., Vogel-Claussen J., Haverich A., Schäfer A., Bauersachs J. Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clin Res Cardiol. 2016; 105:283-96. doi: 10.1007/s00392-015-0941-1

11. Remmelink M., Sjauw K.D., Henriques J., de Winter R.J., Koch K.T., van der Schaaf R.J. et al. Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheter Cardiovasc Interv. 2007; 70:532–7. DOI: 10.1002/ccd.21160

12. Burkhoff D., Cohen H., Brunckhorst C., O’Neill W.W.; TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006; 152:469.e1-8. DOI: 10.1016/j.ahj.2006.05.031

13. Koutouzis M., Kolsrud O., Albertsson P., Matejka G., Grip L., Kjellman U. Percutaneous coronary intervention facilitated by extracorporeal membrane oxygenation support in a patient with cardiogenic shock. Hellenic J Cardiol. 2010; 51:271–4.

14. O’Neill W.W., Kleiman N.S., Moses J., Henriques J.P., Dixon S., Massaro J. et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012; 126:1717–27. doi: 10.1161/CIRCULATIONAHA.112.098194

15. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B. et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44–122. doi: 10.1016/j.jacc.2011.08.007.

16. Kosuga K., Tamai H., Ueda K., Hsu Y.S., Kawashima A., Tanaka S. et al. Initial and long-term results of angioplasty in unprotected left main coronary artery. Am J Cardiol. 1999; 83:32–7.

17. Wallace T.W., Berger J.S., Wang A., Velazquez E.J., Brown D.L. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009; 103:355–60. doi: 10.1016/j.amjcard.2008.09.088.

18. Maini B., Naidu S.S., Mulukutla S., Kleiman N., Schreiber T., Wohns D., Dixon S., Rihal C., Dave R., O'Neill W. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USA Impella Registry. Catheter Cardiovasc Interv. 2012; 80:717-25. doi: 10.1002/ccd.23403

19. Nellis S.H., Liedtke A.J., Whitesell L. Small coronary vessel pressure and diameter in an intact beating rabbit heart using fixedposition and freemotion techniques. Circ Res. 1981; 49:342–53.

20. Бузаев И.В., Плечев В.В., Николаева И.Е. Принятие решения о виде реваскуляризации при стабильной ишемической болезни сердца в сложных клинических случаях. Эндоваскулярная хирургия. 2017; 4 (2): 112–24. DOI: 10.24183/2409-4080-2017-4-2-112-124

21. Curtis J.P., Rathore S.S., Wang Y., Chen J., Nallamothu B.K., Krumholz H.M. Use and effectiveness of intraaortic balloon pumps among patients undergoing high risk percutaneous coronary intervention: insights from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2012; 5:21–30. doi: 10.1161/CIRCOUTCOMES.110.960385.

22. Kovacic J.C., Kini A., Banerjee S., Dangas G., Massaro J., Mehran R., Popma J., O'Neill W.W., Sharma S.K. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. J Interv Cardiol. 2015; 28:32-40. doi: 10.1111/joic.12166.

23. Goldberg R.J., Gore J.M., Alpert J.S., Osganian V., de Groot J., Bade J., Chen Z., Frid D., Dalen J.E. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a communitywide perspective, 1975 to 1988. N Engl J Med. 1991; 325:1117–22. DOI: 10.1056/NEJM199110173251601

24. Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999; 341:625–34. DOI: 10.1056/NEJM199908263410901

25. Kohsaka S., Menon V., Lowe A.M., Lange A.M., Dzavik V., Sleeper L.A., Hochman J.S.; SHOCK Investigators. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Int Med. 2005; 165:1643–1650. DOI: 10.1001/archinte.165.14.1643

26. Hochman J.S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003; 107:2998–3002. DOI: 10.1161/01.CIR.0000075927.67673.F2

27. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K. E. et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33:1787–1847. doi: 10.1093/eurheartj/ehs104.

28. Marshall J.C., Cook D.J., Christou N.V., Bernard G.R., Sprung C.L., Sibbald W.J. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med .1995; 23:1638–52.

29. Fincke R., Hochman J.S., Lowe A.M., Menon V., Slater J.N., Webb J.G., LeJemtel T.H., Cotter G.; SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004; 44: 340–8. DOI: 10.1016/j.jacc.2004.03.060

30. Torre-Amione G., Milo-Cotter O., Kaluski E., Perchenet L., Kobrin I., Frey A., Rund M.M., Weatherley B.D., Cotter G. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail .2009; 15:639–44. doi: 10.1016/j.cardfail.2009.04.001.

31. Atkinson T.M., Ohman E.M., O'Neill W.W., Rab T., Cigarroa J.E.; Interventional Scientific Council of the American College of Cardiology. A Practical Approach to Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2016. Vol. 9. No. 9: 871-883 doi: 10.1016/j.jcin.2016.02.046.

32. Seyfarth M., Sibbing D., Bauer I., Fröhlich G., Bott-Flügel L., Byrne R., Dirschinger J., Kastrati A., Schömig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008; 52:1584–8. doi: 10.1016/j.jacc.2008.05.065.

33. Kapur N.K., Paruchuri V., Jagannathan A., Steinberg D., Chakrabarti A.K., Pinto D. et al. Mechanical circulatory support for right ventricular failure. JACC Heart Fail. 2013; 1:127–34. doi: 10.1016/j.jchf.2013.01.007

34. Kapur N.K., Jumean M., Ghuloom A., Аghili N., Vassallo C., Kiernan M.S., DeNofrio D., Pham D.T.. First successful use of 2 axial flow catheters for percutaneous biventricular circulatory support as a bridge to a durable left ventricular assist device. Circ Heart Fail. 2015; 8:1006–8. doi: 10.1161/CIRCHEARTFAILURE.115.002374.

35. Brooks S.C., Anderson M.L., Bruder E., Daya M.R., Gaffney A., Otto C.W., Singer A.J., Thiagarajan R.R., Travers A.H. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132:S436–43. doi: 10.1161/CIR.0000000000000260.

36. Daya M.R., Schmicker R.H., Zive D.M., Rea T.D.4, Nichol G., Buick J.E. et al.; esuscitation Outcomes Consortium Investigators.Out-of-hospital cardiac arrest survival improving over time: Results from the Resuscitation Outcomes Consortium (ROC). Resuscitation. 2015; 91:108–15. doi: 10.1016/j. resuscitation.2015.02.003

37. Jumean M., Pham D.T., Kapur N.K. Percutaneous bi-atrial extracorporeal membrane oxygenation for acute circulatory support in advanced heart failure. Catheter Cardiovasc Interv. 2015; 85:1097–9. doi: 10.1002/ccd.25791.

38. Chen Y.S., Lin J.W., Yu H.Y., Ko W.J., Jerng J.S., Chang W.T. et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet. 2008; 372:554–61. doi: 10.1016/S0140-6736(08)60958-7.

39. Maekawa K., Tanno K., Hase M., Mori K., Asai Y. Extracorporeal cardiopulmonary resuscitation for patients with out-of-hospital cardiac arrest of cardiac origin: a propensitymatched study and predictor analysis. Crit Care Med. 2013; 41:1186–96. doi: 10.1097/CCM.0b013e31827ca4c8.

40. Sakamoto T., Morimura N., Nagao K., Asai Y.1, Yokota H., Nara S. et al.; AVE-J Study Group Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest: a prospective observational study. Resuscitation. 2014; 85:762–8. doi: 10.1016/j.resuscitation.2014.01.031

41. Jung C., Janssen K., Kaluza M., Fuernau G., Poerner T.C., Fritzenwanger M., Pfeifer R., Thiele H., Figulla H.R. Outcome predictors in cardiopulmonary resuscitation facilitated by extracorporeal membrane oxygenation. Clin Res Cardiol. 2015; 105:196–205. doi: 10.1007/s00392-015-0906-4

42. Waksman R., Weiss A.T., Gotsman M.S., Hasin Y. Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J. 1993; 14:71–4.

43. Ohman E.M., Nanas J., Stomel R.J., Leesar M.A., Nielsen D.W., O'Dea D. et al.; TACTICS Trial. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis. 2005; 19:33–9. DOI: 10.1007/s11239-005-0938-0

44. Burkhoff D., Naidu S.S. The science behind percutaneous hemodynamic support: a review and comparison of support strategies. Catheter Cardiovasc Interv. 2012; 80:816–29. doi: 10.1002/ccd.24421.

45. Thiele H., Sick P., Boudriot E., Diederich K.W., Hambrecht R., Niebauer J., Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005; 360:1276–83. DOI: 10.1093/eurheartj/ehi161

46. Kawashima D., Gojo S., Nishimura T., Itoda Y., Kitahori K., Motomura N., Morota T., Murakami A., Takamoto S., Kyo S., Ono M. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J. 2011; 57:169–76. doi: 10.1097/MAT.0b013e31820e121c.

47. Pavlides G.S., Hauser A.M., Stack R.K., Dudlets, P.I., Grines, C., Timmis, G.C., O'Neill, W.W. Effect of peripheral cardiopulmonary bypass on left ventricular size, afterload and myocardial function during elective supported coronary angioplasty. J Am Coll Cardiol. 1991; 18:499-505.

48. Coylewright M., Mack M.J., Holmes D.R .Jr., O’Gara P.T. A call for an evidence-based approach to the Heart Team for patients with severe aortic stenosis. J Am Coll Cardiol. 2015; 65:1472–80. doi: 10.1016/j.jacc.2015.02.033.

49. Myat A., Patel N., Tehrani S., Banning A.P., Redwood S.R., Bhatt D.L. Percutaneous circulatory assist devices for high-risk coronary intervention. J Am Coll Cardiol Intv. 2015; 8:229–44. doi: 10.1016/j.jcin.2014.07.030.

50. Cheng R., Hachamovitch R., Kittleson M., Patel J., Arabia F., Moriguchi J., Esmailian F., Azarbal B. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014; 97:610–6. doi: 10.1016/j.athoracsur.2013.09.008